Orexo completes bond buyback program

The two companies have decided to terminate the partnership agreement, covering the rights for Orexo to commercialize the digital mental health program for depression, Deprexis, in the US.

Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for Xbrane´s Nivolumab Biosimilar candidate (referencing Opdivo).

Kancera has announces the decision to focus its business on developing the company’s fractalkine blocking candidate drugs KAND567 and KAND145 to treat cardiovascular diseases, initially with focus on treatment of ST-elevation myocardial infarction (STEMI).

The company has announced a capital investment in the United States focused on expanding its research and manufacturing footprint by the end of 2026.

Leon Wang, Executive Vice President International and AstraZeneca China President, is cooperating with an ongoing investigation by Chinese authorities.

Ascendis Pharma has granted Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases.

Takara Bio Europe has announced the expansion of its Gothenburg facility with the addition of a custom manufacturing lab, which came into operation on October 1st.